AstraZeneca has agreed to invest $2 billion in Summit Therapeutics to accelerate development of ivonescimab (PD-1xVEGF) and advance ADC combination strategies. The partners plan to begin by testing ivonescimab with AstraZeneca’s CLDN18.2-directed antibody-drug conjugate in gastrointestinal cancers, signaling a push to expand PD-1xVEGF’s role beyond standalone bispecific use.